INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery
Treatment with INO-3107 achieved statistical significance... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 16, 2023 Category: Pharmaceuticals Source Type: clinical trials
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial
INO-3107 demonstrated statistical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 13, 2022 Category: Pharmaceuticals Source Type: clinical trials
A Phase I Study of Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Conditions: Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Papillomaviridae Intervention: Drug: PRGN-2012 Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2021 Category: Research Source Type: clinical trials
Lenvatinib and Pembrolizumab In HPV-associated RRP
Conditions: Human Papilloma Virus; Recurrent Respiratory Papillomatosis Interventions: Drug: Lenvatinib; Drug: Pembrolizumab Sponsors: Massachusetts General Hospital; Eisai Inc.; Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2020 Category: Research Source Type: clinical trials
